Exploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes

Clicks: 10
ID: 333062
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #364 of 378 articles by views in american journal of epidemiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 378 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Understanding treatment effect heterogeneity (TEH) is essential to improve care for patients living with chronic diseases like type 2 diabetes. Individual responses to treatment can vary substantially, and identifying the factors that drive TEH may enable increased personalization of treatment and follow-up. In this study, we conduct an exploratory analysis of TEH for glucagon-like peptide-1 receptor agonists used to treat type 2 diabetes. Endpoints are defined using hemoglobin A1c measurements, body mass index, and blood pressure. We use causal forests to conduct global tests for TEH, estimate variable importances to rank candidate effect modifiers, and estimate the magnitude of heterogeneity. Data from three clinical trials are analyzed: SUSTAIN 6 (subcutaneous semaglutide versus placebo, n=3297), PIONEER 6 (oral semaglutide versus placebo, n=3183), and LEADER (subcutaneous liraglutide versus placebo, n=9340), pooled to 13,670 patients after exclusions. Baseline hemoglobin A1c ranks highest among candidate effect modifiers across methods, and kidney function ranks next in the relative risk causal forest; we discuss their clinical implications. The magnitude estimates, however, show that the variation these covariates jointly explain is small. As such, large covariate-driven heterogeneity can be ruled out in these trials, and the average treatment effect provides a reasonable summary for most patients.
Reference Key
openalex_W7223021278 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Luke Keele, Matteo Bonvini, Andrea Marheim Storås, Vik Shirvaikar, Haodong Li, Nils B. Jørgensen, Afshin Salsali, M. Medici, Andrew Mertens, Kajsa Kvist
Are you one of these authors? Claim your profile
Journal american journal of epidemiology
Year 2026
DOI
10.1093/aje/kwag261
URL
https://doi.org/10.1093/aje/kwag261
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.